Small molecule lysosomal glycosaminoglycan binders for targeted therapeutic research

Overview

This research program develops small molecule binders targeting glycosaminoglycans (GAGs) within lysosomes. The approach combines the known GAG-binding properties of surfen and its analogues with morpholine, a moiety widely used to direct small molecules to lysosomes. The resulting hybrid compounds are designed to selectively engage GAGs in the lysosomal compartment, supporting research into diseases where lysosomal GAG accumulation plays a role, including certain lysosomal storage disorders.

The value proposition is a chemically rational, structure-based strategy to create lysosome-targeted GAG binders. By integrating two validated design elements—surfen-derived GAG affinity and morpholine-mediated lysosomal localization—the program offers a practical starting point for partners interested in exploring lysosomal GAG biology or developing chemical tools for related therapeutic areas.

Technical specifications

Core design strategy:

• Uses surfen as a structural template for GAG binding, leveraging its established interaction with heparan sulfate and related polysaccharides
• Incorporates morpholine as a lysosome-targeting moiety to direct compounds to the lysosomal compartment
• Generates a series of analogues, including morpholine-incorporated surfen, oxalyl surfen, and diglycolyl surfen variants

Key structural features:

• Dimeric molecular architecture of surfen and its aminoquinoline ring systems, which is essential for heparan sulfate interaction
• Morpholine placement on the quinoline ring, with additional analogues designed to investigate how morpholine affects the amino group responsible for GAG binding
• Rational structure–activity relationship design informed by prior surfen analogue studies

Validation approach:

• In vitro assays to evaluate GAG binding, including fibroblast growth factor 2 binding inhibition in wild-type CHO cells
• Planned in vitro and in vivo evaluation of synthesized compounds
• Quantitative assessment of interactions with cell surface and lysosomal heparan sulfate

Technology readiness level

The program is at an early-to-mid stage of preclinical research. The GAG-binding properties of surfen and several dimeric analogues have been previously characterized, and morpholine-based lysosomal targeting has been demonstrated across multiple optical and probe molecules. Current work focuses on synthesizing the proposed hybrid compounds and validating their lysosomal GAG-binding activity through in vitro assays, with in vivo evaluation planned as a next step. The technology is best suited for collaborative development, tool compound generation, or further optimization toward specific lysosomal GAG-related disease applications.